Clinical Trial Update: Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and tolerability of atogepant 60 mg daily for prevention of episodic migraine has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Episodic

Drugs mentioned

• Atogepant (Atogepant)

Snippet

Sponsor: Allergan | Conditions: Episodic Migraine | Phase 3 | Status: COMPLETED | Results posted: 2021-06-15